Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

ABSTRACT: After exposing a panel of non-small cell lung cancer (NSCLC) cell lines to cytotoxic CD8+ T-cells, we found SERPINB9 to be the most differentially expressed gene between the cell lines most and least resistant to T-cell killing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE214992 | GEO | 2022/10/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genomic correlates of response to immune checkpoint blockade.

Project description: Not available

| S-EPMC6599710 | biostudies-literature

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.

Project description: Not available

| S-EPMC6761178 | biostudies-literature

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.

Project description: Not available

| S-EPMC7865024 | biostudies-literature

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Project description: Not available

| S-EPMC6119118 | biostudies-literature

IMMUNE CORRELATES OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN ACUTE MYELOID LEUKAEMIA

Project description:Immunological classifiers that predict patient outcome and therapeutic responses have been constructed through targeted immune gene expression profiling of pre-treatment bone marrow samples from patients with acute myeloid leukaemia treated with pembrolizumab and hypomethylating agent azacytidine (clinicaltrials.gov identifier: NCT02845297).

2022-09-16 | GSE178926 | GEO

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy.

Project description: Not available

| S-EPMC8036296 | biostudies-literature

Conserved interferon-gamma signaling and decreased immune exclusion programs in responses to immune checkpoint blockade therapy

Project description:Purpose: We treated melanoma cell lines with IFNG to assess which ones would be resistant or responsive to T-cell attack. Methods: We treated the melanoma cell lines with IFNG and then sequenced them at 6 hours to assess changes the transcriptome. Results: Unless the cell lines had JAK1 or JAK2 KO, they responded very consistently with human melanocytes (normals), revealing a consistent signature for IFNG response in melanoma. Conclusions: IFNG signaling is conserved in melanoma cell lines, and there are genes that go down in IFNG that allow immune infiltration to make immune blockade response possible.

2020-07-24 | GSE154996 | GEO

AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML

Project description:T cells are important for the control of acute myeloid leukemia (AML), a common and often deadly malignancy. We observed that some AML patient samples are resistant to killing by human engineered cytotoxic CD4+ T cells. Single-cell RNA-seq of primary AML samples and CD4+ T cells before and after their interaction uncovered transcriptional programs that correlate with AML sensitivity or resistance to CD4+ T cell killing. Resistance-associated AML programs were enriched in AML patients with poor survival, and killing-resistant AML cells did not engage T cells in vitro. Killing-sensitive AML potently activated T cells before being killed, and upregulated ICAM1, a key component of the immune synapse with T cells. Without ICAM1, killing-sensitive AML became resistant to killing to primary ex vivo-isolated CD8+ T cells in vitro, and engineered CD4+ T cells in vitro and in vivo. Thus, ICAM1 on AML acts as an immune trigger, allowing T cell killing, and could affect AML patient survival in vivo.

2024-05-09 | GSE254282 | GEO

Characterization of a novel mouse model of undifferentiated pleomorphic sarcoma that is lymphocyte poor, macrophage rich, and resistant to immune checkpoint blockade

Project description:Sarcomas are rare, difficult to treat, mesenchymal lineage tumours that disproportionately affect children and young adults. Immunologically-based therapies have improved outcomes for numerous adult cancers, however, such approaches have proven ineffective for the majority of individuals with advanced sarcomas. Clinically relevant, immunologically-competent, and transplantable pre-clinical sarcoma models are needed in order to test and develop novel immunologically-based therapies for sarcoma. Herein we show that Cre- lox P-mediated simultaneous activation of Kras G12D , and deletion Trp53, in the hindlimb muscles of C57Bl/6 mice results in the development of highly penetrant, rapid onset undifferentiated pleomorphic sarcomas (UPS). The latter represents a model one of the most common human sarcoma subtypes both histologically and genetically. Furthermore, cell lines derived from the UPS tumors induced in C57Bl/6 mice can be transplanted into the hindlimbs or lungs of naïve, immune competent syngeneic mice. Immunological characterization of both the spontaneous and transplanted UPS tumours demonstrates an immunologically- ‘quiescent’ microenvironment, characterized by a paucity of lymphocytes and spontaneous adaptive immune pathways in addition to dense macrophage infiltrates. UPS cell line induced tumours demonstrate mildly increased lymphocytic infiltrates as compared with the spontaneous UPS tumours, furthermore, growth of transplanted UPS was unaltered in lymphocyte deficient hosts. Despite expression of PD-1 on the tumour infiltrating lymphocytes, UPS tumours were resistant to immunological checkpoint blockade. This syngeneic transplantable UPS model that recapitulates many of the immunological features of human UPS will prove invaluable for the preclinical development and evaluation of novel immunotherapeutic approaches for targeting sarcomas.

2021-06-24 | GSE174540 | GEO

Cancer immunotherapy using checkpoint blockade.

Project description: Not available

| S-EPMC7391259 | biostudies-literature